CURRENT
ISSUE
1733

Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class nitric oxide-releasing agent, has been approved by the FDA for topical treatment of molluscum contagiosum in patients ≥1 year old. It is the second drug to become available in the US for treatment of molluscum contagiosum and the first that can be applied by the patient or caregiver at home; cantharidin 0.7% solution (Ycanth), which is applied by a healthcare professional, was approved earlier for use in patients ≥2 years old.1

MOLLUSCUM CONTAGIOSUM ― A skin infection caused by...  Continue reading

Coming Soon
Drugs and Devices for Weight Management
Mepolizumab (Nucala) for COPD
Clesrovimab (Enflonsia) for Prevention of Severe RSV Diseases in Young Children